

Finding NEMO: NMOSD and MOGAD 101 Review Course

Saturday, January 21, 2023
10:45 a.m. to 5:00 p.m. EST
presented virtually via Zoom

Overall Learning Objectives:

By the end of this program, participants will be able to:

1. Review clinical, serological and radiological features associated with neuromyelitis optica spectrum disorder (NMOSD).
2. Review clinical, serological and radiological features associated with anti-myelin oligodendrocyte glycoprotein (MOG) antibody associated disease (MOGAD).
3. Discuss treatment strategies for NMOSD and MOGAD based on available evidence.

Time	Speaker	Topic
Part 1: Introduction to NMOSD and MOGAD		
10:45am-11:00am	Dr. Courtney Casserly	Warm up and pre-testing questions
11:00am-11:30am	Dr. Romain Marignier	Overview & Primer on Immunopathogenesis of NMOSD and MOGAD
	<p><i>By the end of this session, participants will be able to:</i></p> <ol style="list-style-type: none"> 1. <i>Review the historical context of the discovery of the aquaporin-4 antibody, and more recently the anti-MOG antibody, in disease identification and treatment.</i> 2. <i>Compare and contrast the immunopathogenesis of neuromyelitis optica spectrum disorder (NMOSD) and MOG associated disease (MOGAD).</i> 	
11:30am-12:00pm	Dr. Dalia Rotstein	Overview of Diagnostic Criteria for NMOSD and International Recommendations for MOGAD
	<p><i>By the end of this session, participants will be able to:</i></p> <ol style="list-style-type: none"> 1. <i>Review the clinical and radiological features of NMOSD.</i> 2. <i>Compare and contrast the clinical and radiological features of NMOSD vs MOGAD.</i> 	
12:00pm-12:30pm	Dr. Adrian Budhram	Serum testing for NMOSD and MOGAD
	<p><i>By the end of this session, participants will be able to:</i></p> <ol style="list-style-type: none"> 1. <i>Describe the serological antibody testing for NMOSD-aquaporin-4 antibody testing (including sensitivity and specificity).</i> 2. <i>Describe the serological testing for MOGAD-myelin oligodendrocyte glycoprotein antibody (including sensitivity, specificity) in MOGAD.</i> 3. <i>Compare and contrast cerebrospinal fluid profiles in NMOSD, MOGAD and MS.</i> 	
12:30pm-12:45pm	Q&A with Part 1 Panelists	Drs. Marignier, Rotstein, & Budhram
	<i>Moderated by Dr. Courtney Casserly</i>	
12:45pm-1:00pm	<i>Break</i>	

Time	Speaker	Topic
Part 2: NMOSD and MOGAD – Making the Diagnosis Accurately		
1:00pm-1:30pm	Dr. Jodie Burton	Distinct Neuroimaging Features of NMOSD and MOGAD
	<p><i>By the end of this session, participants will be able to:</i></p> <ol style="list-style-type: none"> 1. Describe MRI features of NMOSD in the optic nerves, brain and spinal cord. 2. Describe MRI features of MOGAD in the optic nerves, brain and spinal cord. 3. Compare and contrast imaging features between NMOSD, MOGAD and MS. 	
1:30pm-2:00pm	Dr. Kazuo Fujihara	Clinical Pearls/Red Flags: Distinguishing NMOSD and MOGAD from Presentations of MS
	<p><i>By the end of this session, participants will be able to:</i></p> <ol style="list-style-type: none"> 1. Develop an approach to optic neuritis, keeping in mind a differential diagnosis of neuromyelitis optica spectrum disorder (NMOSD) and MOG associated disease (MOGAD). 2. Develop an approach to transverse myelitis, keeping in mind a differential diagnosis of neuromyelitis optica spectrum disorder (NMOSD) and MOG associated disease (MOGAD). 3. Compare and contrast the clinical features of NMOSD vs MOGAD. 	
2:00pm-2:30pm	Drs. Jodie Burton & Jonathan Krett	NMOSD and MOGAD Case Vignettes
	<p><i>By the end of this session, participants will be able to:</i></p> <p><i>Using a case-based approach:</i></p> <ol style="list-style-type: none"> 1. Develop an approach to optic neuritis, keeping in mind a differential diagnosis of neuromyelitis optica spectrum disorder (NMOSD) and MOG associated disease (MOGAD). 2. Develop an approach to transverse myelitis, keeping in mind a differential diagnosis of neuromyelitis optica spectrum disorder (NMOSD) and MOG associated disease (MOGAD). 	
2:30pm-2:45pm	Q&A with Part 2 Panelists	Drs. Burton, Fujihara, & Krett
	Moderated by Dr. Courtney Casserly	
2:45pm-3:00pm	Mid-course Break	

Time	Speaker	Topic
Part 3: Treating NMOSD and MOGAD		
3:00pm-3:30pm	Dr. Alexandra Muccilli	Acute Relapse Management: Considerations for NMOSD and MOGAD
	<p><i>By the end of this session, participants will be able to:</i></p> <ol style="list-style-type: none"> 1. Compare and contrast the pharmacological treatments appropriate for the acute treatment of NMOSD vs MOGAD. 2. Recognize the role of plasma exchange in the acute treatment of NMOSD. 	
3:30pm-4:00pm	Dr. Courtney Casserly	Long-term treatments for NMOSD and MOGAD

	<p><i>By the end of this session, participants will be able to:</i></p> <ol style="list-style-type: none"> <i>1. Review medications appropriate for the long-term treatment of NMOSD.</i> <i>2. Propose an algorithm for the long-term treatment of MOGAD.</i> <i>3. Identify safety issues associated with treatment options in NMOSD and MOGAD, and some risk mitigation strategies in this patient population.</i> 	
4:00pm-4:30pm	Dr. Casserly & Muccilli	Putting it All Together: Case Management on the Ward and in Clinic – 2 illustrative cases
	<i>Moderated by Dr. Christine Tomkinson</i>	
	<p><i>By the end of this session, participants will be able to:</i></p> <p><i>Using a case-based approach:</i></p> <ol style="list-style-type: none"> <i>1. Develop an approach to optic neuritis, keeping in mind a differential diagnosis of neuromyelitis optica spectrum disorder (NMOSD) and MOG associated disease (MOGAD).</i> <i>2. Develop an approach to transverse myelitis, keeping in mind a differential diagnosis of neuromyelitis optica spectrum disorder (NMOSD) and MOG associated disease (MOGAD).</i> 	
4:30pm-4:45pm	Q&A with Part 3 Panelists	Drs. Muccilli & Casserly case discussions / Q&A
	<i>Moderated by Dr. Christine Tomkinson</i>	
4:45pm-5:00pm	Dr. Courtney Casserly	Course wrap-up and post-event evaluation Post-test at end of course

**All times are Eastern Standard Time*

25% of this program is dedicated to participant interaction.

MOC Section 1

This event is an Accredited Group Learning Activity (Section 1) as defined by the Maintenance of Certification Program of the Royal College of Physicians and Surgeons of Canada, and approved by Continuing Professional Development, Schulich School of Medicine & Dentistry, Western University. You may claim a maximum of 3 hours (credits are automatically calculated).

MOC Section 3 – Self Assessment

This activity is an Accredited Self Assessment Program (Section 3) as defined by the Maintenance of Certification Program of The Royal College of Physicians & Surgeons of Canada, and approved by Continuing Professional Development, Schulich School of Medicine & Dentistry, Western University. You may claim a maximum of 1.5 hours (credits are automatically calculated).

This program has received educational grants from:
Alexion Canada & Roche Canada